Sinovac COVID-19 vaccine–induced cutaneous leukocytoclastic vasculitis
Rungrot Bencharattanaphakhi, Pawinee Rerknimitr
Abstract
During the COVID-19 pandemic, several vaccine platforms have been generated against this virus, including inactivated whole-virus vaccines, namely CoronaVac (Sinovac Life Sciences).1 It is used particularly in Asia, the Middle East, and South America.2 Dermatologic reactions such as erythema, swelling, and urticaria have been reported.1 Cutaneous vascular inflammation, however, has not been reported from the use of Sinovac (CoronaVac). We, herein, report 2 cases of CoronaVac-induced cutaneous vasculitis.
Topics & Concepts
MedicineLeukocytoclastic vasculitisErythemaCoronavirus disease 2019 (COVID-19)Cutaneous VasculitisDermatologyVasculitis2019-20 coronavirus outbreakPandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyImmunologyPathologyDiseaseOutbreakInfectious disease (medical specialty)Dermatological and COVID-19 studiesHeparin-Induced Thrombocytopenia and ThrombosisUrticaria and Related Conditions